N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice - PubMed (original) (raw)

N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice

Oliwia Andries et al. J Control Release. 2015.

Abstract

Messenger RNA as a therapeutic modality is becoming increasingly popular in the field of gene therapy. The realization that nucleobase modifications can greatly enhance the properties of mRNA by reducing the immunogenicity and increasing the stability of the RNA molecule (the Kariko paradigm) has been pivotal for this revolution. Here we find that mRNAs containing the N(1)-methylpseudouridine (m1Ψ) modification alone and/or in combination with 5-methylcytidine (m5C) outperformed the current state-of-the-art pseudouridine (Ψ) and/or m5C/Ψ-modified mRNA platform by providing up to ~44-fold (when comparing double modified mRNAs) or ~13-fold (when comparing single modified mRNAs) higher reporter gene expression upon transfection into cell lines or mice, respectively. We show that (m5C/)m1Ψ-modified mRNA resulted in reduced intracellular innate immunogenicity and improved cellular viability compared to (m5C/)Ψ-modified mRNA upon in vitro transfection. The enhanced capability of (m5C/)m1Ψ-modified mRNA to express proteins may at least partially be due to the increased ability of the mRNA to evade activation of endosomal Toll-like receptor 3 (TLR3) and downstream innate immune signaling. We believe that the (m5C/)m1Ψ-mRNA platform presented here may serve as a new standard in the field of modified mRNA-based therapeutics.

Keywords: 5-methylcytidine (PubChem CID: 92918); Antiviral innate immunity; Gene therapy; Modified RNA; N(1)-methylpseudouridine (PubChem CID: 99543); Nucleobase modifications; Toll-like receptor; mRNA; pseudouridine (PubChem CID: 15047).

PubMed Disclaimer

Cited by

Establishing Preferred Product Characterization for the Evaluation of RNA Vaccine Antigens.
Poveda C, Biter AB, Bottazzi ME, Strych U. Poveda C, et al. Vaccines (Basel). 2019 Sep 27;7(4):131. doi: 10.3390/vaccines7040131. Vaccines (Basel). 2019. PMID: 31569760 Free PMC article. Review.
Mitogen Activated Protein Kinase (MAPK) Activation, p53, and Autophagy Inhibition Characterize the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein Induced Neurotoxicity.
Kyriakopoulos AM, Nigh G, McCullough PA, Seneff S. Kyriakopoulos AM, et al. Cureus. 2022 Dec 9;14(12):e32361. doi: 10.7759/cureus.32361. eCollection 2022 Dec. Cureus. 2022. PMID: 36514706 Free PMC article. Review.
Epitranscriptomics of SARS-CoV-2 Infection.
Izadpanah A, Rappaport J, Datta PK. Izadpanah A, et al. Front Cell Dev Biol. 2022 Apr 8;10:849298. doi: 10.3389/fcell.2022.849298. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35465335 Free PMC article. Review.
New Vaccine Technologies to Combat Outbreak Situations.
Rauch S, Jasny E, Schmidt KE, Petsch B. Rauch S, et al. Front Immunol. 2018 Sep 19;9:1963. doi: 10.3389/fimmu.2018.01963. eCollection 2018. Front Immunol. 2018. PMID: 30283434 Free PMC article. Review.
Advances in COVID-19 mRNA vaccine development.
Fang E, Liu X, Li M, Zhang Z, Song L, Zhu B, Wu X, Liu J, Zhao D, Li Y. Fang E, et al. Signal Transduct Target Ther. 2022 Mar 23;7(1):94. doi: 10.1038/s41392-022-00950-y. Signal Transduct Target Ther. 2022. PMID: 35322018 Free PMC article. Review.

N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice - PubMed (original) (raw)